OXYS ~ Strong outlook for 2016E as Model 615 gains
Post# of 115
Posted On: 12/01/2015 12:37:24 PM
OXYS ~ Strong outlook for 2016E as Model 615 gains traction
OxySure issued a strong outlook for continued growth in 2016E. Management plans on reaching a $10mn annual run rate by the end of the year -- $2.5mn or more in quarterly revenues – as it appears that the company’s flagship OxySure Model 615 continues to gain traction in the market. OXYS recently added new territory sales managers in Indiana and Colorado, which should help the company’s efforts in its drive to wards $10mn in annualized sales. On its 3Q15 earnings call, OxySure management noted that OXYS
was approaching $5mn in annualized revenues in 3Q15 ($4.6mn), and states that OxySure was “on track” to reach a $10mn annualized rate in 2016E. Importantly, OXYS management also said that it was targeting cash flow breakeven by the end of 2016E as well. If OXYS achieves both of these goals in the next 4-5 quarters, reaching cash flow generation and a $10mn annualized run rate, this would be a significant milestone for the company and also prove the powerful
underlying earnings leverage inherent in the business.
http://www.oxysure.com/OXYS%20Update.%20FINAL%2011-25-15.pdf
OxySure issued a strong outlook for continued growth in 2016E. Management plans on reaching a $10mn annual run rate by the end of the year -- $2.5mn or more in quarterly revenues – as it appears that the company’s flagship OxySure Model 615 continues to gain traction in the market. OXYS recently added new territory sales managers in Indiana and Colorado, which should help the company’s efforts in its drive to wards $10mn in annualized sales. On its 3Q15 earnings call, OxySure management noted that OXYS
was approaching $5mn in annualized revenues in 3Q15 ($4.6mn), and states that OxySure was “on track” to reach a $10mn annualized rate in 2016E. Importantly, OXYS management also said that it was targeting cash flow breakeven by the end of 2016E as well. If OXYS achieves both of these goals in the next 4-5 quarters, reaching cash flow generation and a $10mn annualized run rate, this would be a significant milestone for the company and also prove the powerful
underlying earnings leverage inherent in the business.
http://www.oxysure.com/OXYS%20Update.%20FINAL%2011-25-15.pdf
(0)
(0)OxySure Therapeutics, Inc. (OXYS) Stock Research Links
Scroll down for more posts ▼